검색
Silence Therapeutics PLC
SLN관심 목록에 추가
10.390USD
-0.110-1.05%
종가 07/02, 13:00（ET）시세는 15분 지연됩니다
490.76M시가총액
손실P/E TTM
자세한 내용은 Silence Therapeutics PLC 회사
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Silence Therapeutics PLC 정보
종목 코드 SLN
회사 이름Silence Therapeutics PLC
상장일Jan 05, 2010
CEOTooman (Craig A)
직원 수116
유형Depository Receipt
회계 연도 종료Jan 05
주소72 Hammersmith Road
도시LONDON
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United Kingdom
우편 번호W14 8TH
전화442034576900
웹사이트https://www.silence-therapeutics.com/
종목 코드 SLN
상장일Jan 05, 2010
CEOTooman (Craig A)
Silence Therapeutics PLC의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
자주 묻는 질문
Silence Therapeutics PLC의 상위 5대 주주는 누구인가요?
Silence Therapeutics PLC의 상위 5대 주주는 다음과 같습니다: Mr. David Jakob (Dave) Lemus, CPA
Silence Therapeutics PLC(SLN)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Silence Therapeutics PLC의 주식을 보유한 기관은 총 147곳이며, 이들이 보유한 주식의 총 가치는 약 19.17M로 전체 발행 주식의 40.59%를 차지합니다. 이는 2025Q4 대비 -12508865.00 증가한 수치입니다.